New drug combination effective against SARS-CoV-2 infection

More countries with greater resources are opening up for a more normal life. But COVID-19 and the SARS-CoV-2 virus are still a significant threat in large parts of the world.

The lack of medicines that are effective, easy to distribute and easy to obtain are a significant part of the problem.

However, recent research on a new drug combination is showing promising results. The combined use of nafamostat and Pegasys (IFNα) meets all availability and efficacy requirements.

Effective in the laboratory

"This combination effectively suppresses the infection," says Professor Denis Kainov at the Norwegian University of Science and Technology's (NTNU) Department of Clinical and Molecular Medicine (IKOM).

The experiments were performed in cell cultures and hamsters. This does not necessarily mean that the combination works in humans, but it is a good sign.

Nafamostat is already in use as a monotherapy against COVID-19 and is undergoing extensive testing in Japan, among other places. Pegasys (IFNα) is currently used mainly to treat hepatitis C. Combining the two appears to have a positive effect.

"Both drugs attack a factor in our cells called TMPRSS2, which plays a critical role in viral replication," says Magnar Bjørås, a professor in the Department of Clinical and Molecular Medicine.

This could be a hot tip for researchers who are already testing nafamostat in the fight against COVID-19.

Low dosage needed

Only low doses of the combination medicine are needed, as well.

"The low doses of the drugs in combination may have several clinical advantages. including fewer adverse events and improved outcomes for patients," says Aleksandr Ianevski, a doctoral research fellow affiliated with the Department of Clinical and Molecular Medicine.

In other words, the combination medicine can both save lives and make life easier for patients. Nafamostat is relatively inexpensive. The downside of Pegasys (IFNα) is its higher cost.

Officially, 4.55 million people have died from COVID-19 worldwide. But unreported numbers are most likely very large in parts of the world where the cause of death is not always accurately recorded.

The research group is very international, but has its focus in Norway. NTNU's research partners include Oslo University Hospital (Rikshospitalet), the University of Oslo, the French precision medicine company Oncodesign, the University of Tartu in Estonia and the University of Helsinki.

Ianevski, A, Yao R. Lysvand H, Grødeland G, Legrand N, Oksenych V, Zusinaite E, Tenson T, Bjørås M, Kainov DE.
Nafamostat–Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2.
Viruses 2021, 13, 1768. doi: 10.3390/v13091768

Most Popular Now

Novartis provides more than USD 25 million in medi…

Novartis announced that it condemns the war in Ukraine: "The continued acts of unprovoked violence are harming innocent people, and this defies our mission to improve hum...

Findings open way for personalised MS treatment

Currently available therapies to treat multiple sclerosis (MS) lack precision and can lead to serious side effects. Researchers at Karolinska Institutet in Sweden have no...

Pfizer and Biohaven's VYDURA® (rimegepant) granted…

Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the European Commission (EC) has granted marketing authorizatio...

Pfizer shares top-line results from Phase 2/3 EPIC…

Pfizer Inc. (NYSE: PFE) shared top-line results from the Phase 2/3 EPIC-PEP (Evaluation of Protease Inhibition for COVID-19 in Post-Exposure Prophylaxis) study evaluating...

A smarter way to develop new drugs

Pharmaceutical companies are using artificial intelligence to streamline the process of discovering new medicines. Machine-learning models can propose new molecules that ...

Cognitive impairment from severe COVID-19 equivale…

Cognitive impairment as a result of severe COVID-19 is similar to that sustained between 50 and 70 years of age and is the equivalent to losing 10 IQ points, say a team o...

A new toolkit to engineer safe and efficient thera…

Therapies based on engineered immune cells have recently emerged as a promising approach in the treatment of cancer. Compared to traditional drugs, engineered immune cell...

SK bioscience and GSK's adjuvanted COVID-19 vaccin…

SK bioscience and GSK announced submission of a biologics license application for SKYCovione™ a recombinant protein-based COVID-19 vaccine candidate adjuvanted with GSK’s...

Foundation S: Sanofi's new philanthropic spearhead

Sanofi today launches Foundation S - The Sanofi Collective, its philanthropic endowment fund aiming to create healthier futures for generations. Using donations, partners...

Asthma drug can block crucial SARS-CoV-2 protein

A drug used to treat asthma and allergies can bind to and block a crucial protein produced by the virus SARS-CoV-2, and reduce viral replication in human immune cells, ac...

Investigational COVID mucosal vaccine protects aga…

In animal studies that mimic human exposures, an investigational COVID vaccine designed to be taken orally not only protects the host, but also decreases the airborne spr...

Using AI to analyze large amounts of biological da…

Researchers at the University of Missouri are applying a form of artificial intelligence (AI) - previously used to analyze how National Basketball Association (NBA) playe...